Form 4: RAPT Therapeutics Director Michael Giordano Granted Over 250,000 Stock Options

RAPT Therapeutics, Inc. has reported that Director Michael F. Giordano was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 equal monthly installments.

Summary

• Michael F. Giordano, a Director of RAPT Therapeutics, Inc. (RAPT), was granted 257,832 Director Stock Options.
• The options have an exercise price of $0.93 per share.
• The grant date for these options was May 29, 2025.
• The options will vest in 12 equal monthly installments starting from the grant date.
• The expiration date for these options is May 28, 2035.
• Following this transaction, Michael F. Giordano beneficially owns 257,832 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns the director's interests with shareholder value, which is a common and generally favorable corporate governance practice, despite potential future dilution.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Stock options are a common form of non-cash compensation, preserving company cash flow.

Negatives

• The exercise of these options in the future could lead to a dilution of existing shareholders' equity, as new shares would be issued.

Risks

• The value of the stock options is dependent on the future market price of RAPT Therapeutics' common stock; if the stock price does not exceed the exercise price, the options may not be valuable.
• The options are subject to a vesting schedule, meaning the director must remain with the company for the options to fully vest and become exercisable.

Future Outlook

The granted stock options will vest in 12 equal monthly installments from May 29, 2025, indicating a future increase in the director's exercisable equity holdings over the next year.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of equity-based compensation to attract and retain talent and align leadership interests with long-term shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in the biotechnology sector, aligning their interests with shareholders.
• This filing does not provide specific benchmarks or comparable company data (e.g., from companies like Amgen, Gilead Sciences, or Biogen) to assess the size or terms of this particular grant against industry averages or specific peer compensation structures.

Corporate Governance

Related Party Transactions

• The grant of stock options by RAPT Therapeutics, Inc. to its Director, Michael F. Giordano, constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned director incentives for long-term company growth and stock performance.

Next Steps

• The options will continue to vest in 12 equal monthly installments from the grant date of May 29, 2025, leading to an increase in the director's exercisable options over the next year.

Key Dates

Keywords

RAPT Therapeutics, Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership, RAPT